Merck's first HIF-2 inhibitor two phase III studies results in renal cell carcinoma released.

Wisdom Financial App learned that on October 28th, Merck (MRK.US) announced two pieces of news: 1) The phase III LITESPARK-011 trial evaluating the dual oral therapy of Welireg (belzutifan) in combination with lenvatinib for the treatment of advanced renal cell carcinoma patients who have experienced disease progression after prior anti-PD-1/L1 therapy achieved one of its primary endpoints of progression-free survival (PFS). Belzutifan is Merck's first oral hypoxia-inducible factor-2 (HIF-2) inhibitor.